hotspot
I was wrong about Geron.
For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.
advertisement
On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Asbestos ban is immediate, but health effects will linger for decades
Next article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Duchenne breakthrough therapy leaves behind pioneering families
